Skip to search boxSkip to navigationSkip to main content

Acute, subacute and chronic effect of cyclosporin-A on mean arterial pressure of rats with severe spinal cord contusion

  • Samanta E. Romerob(Author)
    ,
  • Guadalupe Bravob(Author)
    ,
  • Enrique Hongb(Author)
    ,
  • Guillermo Rojasb(Author)
    ,
  • Antonio Ibarraa, c(Author)
  • ,
  • bCentro de Investigacion y de Estudios Avanzados del Instituto Politécnico Nacional
    ,
  • cCentro de Investigación Camina
Research Output: Contribution to journal Article Peer-review

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 99-102 (4 pages)

Journal (Volume, Issue Number)

Neuroscience Letters (Volume 445, Issue 1)

Publication milestones

  • Published - 07/11/2008

Publication status

Published - 07/11/2008

ISSN

0304-3940

External Publication IDs

  • Scopus: 54849362900
  • PubMed: 18775474

Abstract

Cyclosporin-A (CsA) protects and regenerates the neural tissue after spinal cord (SC) injury. These beneficial effects are achieved when CsA is administered at a dose of 2.5 mg/kg/12 h during the first 2 days after lesion. In view of these observations, it is realistic to envision that, CsA could be tested in SC-clinical trials. Since CsA is a drug strongly related to hypertension, results imperative to evaluate experimentally the effect of the above CsA-dose regimen on blood pressure. For this purpose, one hundred and twenty adult rats were subjected (10 groups) or not (10 groups) to SC-injury. Five injured and five Sham-operated groups received CsA. The remaining groups received only vehicle. Mean arterial pressure (MAP) was recorded from these animals at acute (6 and 24 h post surgery; p.s.), subacute (96 h), or chronic (30 days) stages of injury. In the latter, the therapy (CsA or vehicle) was administered only during the first 2 days p.s. or daily during 30 days of follow-up. The results of this study showed that SC-injury by itself induces a significant decrease of MAP during the acute and subacute phases of injury. CsA therapy was able to reestablish MAP parameters to control values in these phases. Regardless the therapy, a reestablishment of MAP was observed in chronic stages. Only the daily administration of CsA induced a significant increase in MAP, however; such variation remained into the normal ranges of MAP for rats. The potential benefits offered by CsA support its usefulness after SC-injury.